GLPwatch
Papers (9189)
Page 86 of 154, ranked by citation count.
- Drug treatment of obesity.
- Effects of <i>PPARD</i> gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus.
- Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice.
- Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease.
- The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.
- Factors associated with successful weight loss after liraglutide treatment for obesity.
- Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.
- Incretin concepts.
- Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.
- Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.
- Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
- Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.
- Cardioprotective Actions of a Glucagon-like Peptide-1 Receptor Agonist on Hearts Donated After Circulatory Death.
- Liraglutide modulates olfactory ensheathing cell migration with activation of ERK and alteration of the extracellular matrix.
- Liraglutide alleviates sepsis-induced acute lung injury by regulating pulmonary surfactant through inhibiting autophagy.
- Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.
- Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes.
- Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo.
- Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
- A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
- Augmented nephroprotective effect of liraglutide and rabeprazole via inhibition of OCT2 transporter in cisplatin-induced nephrotoxicity in rats.
- Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
- Administration of Exendin-4 but not CCK alters lick responses and trial initiation to sucrose and intralipid during brief-access tests.
- GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
- A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
- Semaglutide and social media: implications for young women with polycystic ovarian syndrome.
- Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
- Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?
- Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
- Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified <i>Xenopus</i> glucagon-like peptide-1 analogs.
- Liraglutide Exerts Potential Anti-inflammatory Effect in Type 1 Diabetes by Inhibiting IFN-γ Production <i>via</i> Suppressing JAK-STAT Pathway.
- Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.
- Effects of Metformin on Renal Function, Cardiac Function, and Inflammatory Response in Diabetic Nephropathy and Its Protective Mechanism.
- Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity-Reply.
- The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide.
- Semaglutide and effective weight control.
- Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
- Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain.
- Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.
- Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer.
- Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.
- Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
- Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.
- GHSR-1 agonist sensitizes rat colonic intrinsic and extrinsic neurons to exendin-4: A role in the manifestation of postprandial gastrointestinal symptoms in irritable bowel syndrome?
- Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
- The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study.
- Oxidation of methionine - is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?
- No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.
- Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
- Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
- Protective Effects of Lixisenatide against Lipopolysaccharide-Induced Inflammation Response in MAC-T Bovine Mammary Epithelial Cells: A Therapeutic Implication in Mastitis.
- Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.
- Exenatide and feeding: possible peripheral neuronal pathways.
- Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.
- Primary and Secondary Binding of Exenatide to Liposomes.
- Duodenal-jejunal bypass changes the composition of the gut microbiota.
- Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
- Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan.
- Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events.
- GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.